Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey

The T cell immune response against SARS-CoV-2

(2022) Paul Moss   NATURE IMMUNOLOGY

Inpatient COVID-19 mortality has reduced over time: Results from an observational cohort

(2022) Katie Bechman et al.   PLoS One

CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma

(2022) Akinao Okamoto et al.   Blood Advances

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

(2022) Sabine Haggenburg et al.   Blood Advances

A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience

(2022) Andrea Kuhnl et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

(2022) Ola Blennow et al.   AMERICAN JOURNAL OF HEMATOLOGY

T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine

(2022) Djordje Atanackovic et al.   Journal for ImmunoTherapy of Cancer

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey

(2022) Livio Pagano et al.   BLOOD

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

(2022) Emmanuel Bachy et al.   NATURE MEDICINE

Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study

(2022) Isobel L Ward et al.   BMJ-British Medical Journal

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

(2022) Sabine Haggenburg et al.   JAMA Oncology

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

(2022) Jon Salmanton-García et al.   HemaSphere

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy

(2021) Binod Dhakal et al.   BLOOD

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

(2021) Thomas Gastinne et al.   BRITISH JOURNAL OF HAEMATOLOGY

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

(2021) Vincenzo Marasco et al.   BRITISH JOURNAL OF HAEMATOLOGY

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

(2021) Anne Mea Spanjaart et al.   LEUKEMIA

COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP

(2021) Alessandro Busca et al.   Blood Advances

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

(2020) Paolo Strati et al.   HAEMATOLOGICA

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE